JOHNSON & JOHNSON 
By NEW BRUNSWICK, N.J., Jan. 22, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $17.6 billion for the fourth quarter of 2012, an increase of 8.0% as compared to the fourth quarter of 2011. Operational results increased 9.3% and the negative impact of currency was 1.3%. Domestic sales increased 6.8%, while international sales increased 8.9%, reflecting operational growth of 11.2% and a negative currency impact of 2.3%. Sales for the fourth quarter of 2012 included the impact of the recently completed acquisition of Synthes, Inc., which contributed 5.6% to worldwide operational sales growth, net of the divestiture of the DePuy trauma business. Worldwide sales for the full-year 2012 were $67.2 billion, an increase of 3.4% versus 2011. Operational sales increased 6.1% and the negative impact of currency was 2.7%. Domestic sales increased 3.2%, while international sales increased 3.5%, reflecting operational growth of 8.4% and a negative currency impact of 4.9%. Sales for the full-year 2012 included the impact of the recently completed acquisition of Synthes, Inc., which contributed 3.1% to worldwide operational sales growth, net of the divestiture of the DePuy trauma business.
Net earnings and diluted earnings per share for the fourth quarter of 2012 were $2.6 billion and $0.91, respectively.** Fourth-quarter 2012 net earnings included after-tax special items of $0.8 billion, primarily related to an increase in the litigation accrual and program costs associated with the DePuy ASR(TM) Hip, in-process research and development, and integration and transaction costs related to the acquisition of Synthes, Inc.
Fourth-quarter 2011 net earnings reflect after-tax special items of $2.9 billion as detailed in the accompanying reconciliation of non-GAAP financial measures. Excluding these special items for both periods, net earnings for the current quarter were $3.4 billion and diluted earnings per share were $1.19, representing increases of 7.9% and 5.3%, respectively, as compared to the same period in 2011.*
Net earnings and diluted earnings per share for the full-year 2012 were $10.9 billion and $3.86, respectively.** Full-year net earnings reflect after-tax special items of $3.5 billion in 2012 and $4.2 billion in 2011 as detailed in the accompanying reconciliation of non-GAAP financial measures. Excluding these special items in both periods, net earnings for the full-year 2012 were $14.3 billion and diluted earnings per share were $5.10, representing increases of 3.4% and 2.0%, respectively, as compared with the full year of 2011.*
"Johnson & Johnson delivered solid results in 2012 reflecting continued sales momentum in many parts of our business driven by our focus on delivering meaningful innovation in health care to patients and customers. Our results included strong growth of key products, successful new product launches, and the addition of Synthes to our family of companies," said Alex Gorsky, Chairman and Chief Executive Officer. "In addition, we continued to make important investments building strategic partnerships and in advancing our pipeline, positioning us well for delivering sustainable growth as we enter 2013. I would also like to thank our talented colleagues at Johnson & Johnson for their extraordinary achievements in helping advance health and well-being for patients and customers around the world."
The Company announced earnings guidance for full-year 2013 of $5.35 to $5.45 per share, which excludes the impact of special items.
Worldwide Consumer sales of $14.4 billion for the full-year 2012 represented a decrease of 2.9% versus the prior year, consisting of an operational increase of 0.5% and a negative impact from currency of 3.4%. Domestic sales decreased 2.0%; international sales decreased 3.4%, which reflected an operational increase of 1.9% and a negative currency impact of 5.3%.
Positive contributors to operational results were sales of upper respiratory over-the-counter products; international sales of LISTERINE® oral care products; and U.S. sales of NEUTROGENA® skin care products.
Worldwide Pharmaceutical sales of $25.4 billion for the full-year 2012 represented an increase of 4.0% versus the prior year with an operational increase of 6.8% and a negative impact from currency of 2.8%. Domestic sales increased 0.3%; international sales increased 7.9%, which reflected an operational increase of 13.6% and a negative currency impact of 5.7%.
Primary contributors to operational sales growth were REMICADE® (infliximab), a biologic approved for the treatment of a number of immune-mediated, inflammatory diseases; VELCADE® (bortezomib), a treatment for multiple myeloma; PREZISTA® (darunavir), a treatment for HIV; and a number of recently launched products.
The strong sales results of recently launched products included ZYTIGA® (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer; INVEGA® SUSTENNA®/XEPLION® (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the acute and maintenance treatment of schizophrenia in adults; international sales of INCIVO® (telaprevir), a direct acting antiviral protease inhibitor, for the treatment of genotype-1 chronic hepatitis C virus, in combination with peginterferon alfa and ribavirin, in adults; STELARA® (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis; XARELTO® (rivaroxaban), an oral anticoagulant; and SIMPONI®( )(golimumab), a biologic approved to treat adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Sales results were negatively impacted by generic competition for LEVAQUIN® (levofloxacin), a treatment for bacterial infections and the manufacturing suspension at a third party supplier for DOXIL® (doxorubicin HCl liposome injection)/CAELYX® (pegylated liposomal doxorubicin hydrochloride), a medication to treat ovarian and other cancers.
During the quarter, the U.S. Food and Drug Administration (FDA) granted accelerated approval for SIRTURO(TM) (bedaquiline) tablets for the treatment of pulmonary multi-drug resistant tuberculosis as part of combination therapy in adults. The FDA and the European Commission also approved an expanded indication for ZYTIGA® (abiraterone acetate), in combination with prednisone, allowing for the use before chemotherapy in the treatment of metastatic castration-resistant disease.
In November, the FDA approved XARELTO® (rivaroxaban), an oral anticoagulant, for the treatment of deep vein thrombosis (DVT) and/or pulmonary embolism (PE), and to reduce the risk of recurrence of DVT and PE following initial treatment. In addition, the FDA approved a new 800mg tablet of PREZISTA® (darunavir) for once daily oral administration for the treatment of human immunodeficiency virus (HIV-1) in treatment-naive and treatment-experienced adult patients with no darunavir resistance-associated mutations.
Also during the quarter, a New Drug Application was submitted to the FDA seeking approval for a fixed-dose therapy combining canagliflozin and immediate release metformin to treat patients with type 2 diabetes. Additional submissions included a supplemental Biologics License Application to the FDA and a Type II Variation to the European Medicines Agency requesting approval of STELARA® (ustekinumab) for the treatment of adult patients with active psoriatic arthritis.
Worldwide Medical Devices and Diagnostics sales of $27.4 billion for the full-year 2012 represented an increase of 6.4% versus the prior year with an operational increase of 8.7% and a negative impact from currency of 2.3%. Domestic sales increased 8.7%; international sales increased 4.5%, which reflected an operational increase of 8.6% and a negative currency impact of 4.1%. Sales included the impact of the recently completed acquisition of Synthes, Inc., which contributed 7.9% to worldwide operational sales growth, net of the divestiture of the DePuy trauma business.
Primary contributors to operational growth were sales from the recently completed acquisition of Synthes, Inc. in the Orthopaedics business; a number of products in the Specialty Surgery business; Biosense Webster's electrophysiology products in the Cardiovascular Care business; and Vistakon's disposable contact lenses.
During the quarter, the FDA approved EVARREST(TM) Fibrin Sealant Patch, a novel product that rapidly and reliably aids in stopping problematic bleeding during surgery. The FDA also approved the S.M.A.R.T.® CONTROL® Vascular Stent Systems for use in the superficial femoral artery and/or the proximal popliteal artery.
About Johnson & Johnson
Caring for the world, one person at a time...inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 128,000 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
* Net earnings and diluted earnings per share attributable to Johnson & Johnson, excluding special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the financial schedules accompanying this press release and can be found in the Investor Relations section of the Company's website at www.investor.jnj.com.
** Net earnings and diluted earnings per share attributable to Johnson & Johnson.
NOTE TO INVESTORS
Johnson & Johnson will conduct a meeting with members of the investment community to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.
Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, condensed consolidated statements of earnings, and sales of key products/franchises. Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development and medical devices and diagnostics pipeline of selected products, can be found on the Company's website at www.jnj.com
(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; significant adverse litigation or government action; impact of business combinations; financial distress and bankruptcies experienced by significant customers and suppliers; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and sovereign risk; disruptions due to natural disasters; manufacturing difficulties or delays; and product efficacy or safety concerns resulting in product recalls or regulatory action. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)
Johnson & Johnson and Subsidiaries
----------------------------------
Supplementary Sales Data
(Unaudited; Dollars in Millions) FOURTH QUARTER TWELVE MONTHS
------------------------------- -------------- -------------
Percent Change Percent Change
-------------- --------------
2012 2011 Total Operations Currency 2012 2011 Total Operations Currency
---- ---- ----- ---------- -------- ---- ---- ----- ---------- --------
Sales to customers by
segment of business
Consumer
U.S. $1,203 1,248 (3.6)% (3.6) - $5,046 5,151 (2.0)% (2.0) -
International 2,449 2,420 1.2 3.2 (2.0) 9,401 9,732 (3.4) 1.9 (5.3)
------------- ----- ----- --- --- ---- ----- ----- ---- --- ----
3,652 3,668 (0.4) 0.9 (1.3) 14,447 14,883 (2.9) 0.5 (3.4)
----- ----- ---- --- ---- ------ ------ ---- --- ----
Pharmaceutical
U.S. 3,013 2,887 4.4 4.4 - 12,421 12,386 0.3 0.3 -
International 3,512 3,207 9.5 12.1 (2.6) 12,930 11,982 7.9 13.6 (5.7)
------------- ----- ----- --- ---- ---- ------ ------ --- ---- ----
6,525 6,094 7.1 8.5 (1.4) 25,351 24,368 4.0 6.8 (2.8)
----- ----- --- --- ---- ------ ------ --- --- ----
Med Devices & Diagnostics
U.S. 3,244 2,850 13.8 13.8 - 12,363 11,371 8.7 8.7 -
International 4,137 3,643 13.6 15.8 (2.2) 15,063 14,408 4.5 8.6 (4.1)
------------- ----- ----- ---- ---- ---- ------ ------ --- --- ----
7,381 6,493 13.7 14.9 (1.2) 27,426 25,779 6.4 8.7 (2.3)
----- ----- ---- ---- ---- ------ ------ --- --- ----
U.S. 7,460 6,985 6.8 6.8 - 29,830 28,908 3.2 3.2 -
International 10,098 9,270 8.9 11.2 (2.3) 37,394 36,122 3.5 8.4 (4.9)
------------- ------ ----- --- ---- ---- ------ ------ --- --- ----
Worldwide $17,558 16,255 8.0% 9.3 (1.3) $67,224 65,030 3.4% 6.1 (2.7)
--------- ------- ------ --- --- ---- ------- ------ --- --- ----
Johnson & Johnson and Subsidiaries
----------------------------------
Supplementary Sales Data
(Unaudited; Dollars in Millions) FOURTH QUARTER TWELVE MONTHS
------------------------------- -------------- -------------
Percent Change Percent Change
-------------- --------------
2012 2011 Total Operations Currency 2012 2011 Total Operations Currency
---- ---- ----- ---------- -------- ---- ---- ----- ---------- --------
Sales to customers by
geographic area
U.S. $7,460 6,985 6.8% 6.8 - $29,830 28,908 3.2% 3.2 -
---- ------ ----- --- --- --- ------- ------ --- --- ---
Europe 4,603 4,279 7.6 10.4 (2.8) 16,945 17,129 (1.1) 5.8 (6.9)
Western Hemisphere excluding U.S. 1,941 1,688 15.0 18.7 (3.7) 7,207 6,418 12.3 19.0 (6.7)
Asia-Pacific, Africa 3,554 3,303 7.6 8.5 (0.9) 13,242 12,575 5.3 6.7 (1.4)
International 10,098 9,270 8.9 11.2 (2.3) 37,394 36,122 3.5 8.4 (4.9)
------------- ------ ----- --- ---- ---- ------ ------ --- --- ----
Worldwide $17,558 16,255 8.0% 9.3 (1.3) $67,224 65,030 3.4% 6.1 (2.7)
--------- ------- ------ --- --- ---- ------- ------ --- --- ----
Johnson & Johnson and Subsidiaries
----------------------------------
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures) FOURTH QUARTER
------------------------------------------------ --------------
2012 2011 Percent
---- ----
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers $17,558 100.0 $16,255 100.0 8.0
------------------ ------- ----- ------- ----- ---
Cost of products sold 6,003 34.2 5,338 32.8 12.5
Selling, marketing and administrative expenses 5,661 32.2 5,458 33.6 3.7
Research and development expense 2,331 13.3 2,155 13.3 8.2
In-process research and development 55 0.3 - -
Interest (income) expense, net 89 0.5 148 0.9
Other (income) expense, net 319 1.8 2,858 17.6
Restructuring (income) expense, net - - (20) (0.1)
----------------------------------- --- --- --- ----
Earnings before provision for taxes on income 3,100 17.7 318 1.9 874.8
Provision for taxes on income 533 3.1 100 0.6 433.0
Net earnings 2,567 14.6 218 1.3 1,077.5
------------ ----- ---- --- --- -------
Add: Net loss attributable to noncontrolling interest - - - -
----------------------------------------------------- --- --- --- ---
Net earnings attributable to Johnson & Johnson $2,567 14.6 $218 1.3 1,077.5
---------------------------------------------- ------ ---- ---- --- -------
Net earnings per share attributable to Johnson & Johnson (Diluted) $0.91 $0.08 1,037.5
Average shares outstanding (Diluted) 2,833.4 2,768.9
Effective tax rate 17.2% 31.4%
Adjusted earnings before provision for taxes and net earnings attributable to Johnson & Johnson (1)
Earnings before provision for taxes on income $4,115 23.4 $3,657 22.5 12.5
Net earnings attributable to Johnson & Johnson $3,376 19.2 $3,129 19.2 7.9
Net earnings per share attributable to Johnson & Johnson (Diluted) $1.19 $1.13 5.3
Effective tax rate 18.0% 14.4%
------------------ ---- ----
(1) See Reconciliation of Non-GAAP Financial Measures.
Johnson & Johnson and Subsidiaries
----------------------------------
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures) TWELVE MONTHS
------------------------------------------------ -------------
2012 2011 Percent
---- ----
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers $67,224 100.0 $65,030 100.0 3.4
------------------ ------- ----- ------- ----- ---
Cost of products sold 21,658 32.2 20,360 31.3 6.4
Selling, marketing and administrative expenses 20,869 31.0 20,969 32.3 (0.5)
Research and development expense 7,665 11.4 7,548 11.6 1.6
In-process research and development 1,163 1.7 - -
Interest (income) expense, net 468 0.7 480 0.7
Other (income) expense, net 1,626 2.5 2,743 4.2
Restructuring (income) expense, net - - 569 0.9
----------------------------------- --- --- --- ---
Earnings before provision for taxes on income 13,775 20.5 12,361 19.0 11.4
Provision for taxes on income 3,261 4.9 2,689 4.1 21.3
Net earnings 10,514 15.6 9,672 14.9 8.7
------------ ------ ---- ----- ---- ---
Add: Net loss attributable to noncontrolling interest 339 0.5 - -
----------------------------------------------------- --- --- --- ---
Net earnings attributable to Johnson & Johnson $10,853 16.1 $9,672 14.9 12.2
---------------------------------------------- ------- ---- ------ ---- ----
Net earnings per share attributable to Johnson & Johnson (Diluted) $3.86 $3.49 10.6
Average shares outstanding (Diluted) 2,812.6 2,775.3
Effective tax rate 23.7% 21.8%
Adjusted earnings before provision for taxes and net earnings attributable to Johnson & Johnson (1)
Earnings before provision for taxes on income $18,214 27.1 $17,353 26.7 5.0
Net earnings attributable to Johnson & Johnson $14,345 21.3 $13,867 21.3 3.4
Net earnings per share attributable to Johnson & Johnson (Diluted) $5.10 $5.00 2.0
Effective tax rate 21.2% 20.1%
------------------ ---- ----
(1) See Reconciliation of Non-GAAP Financial Measures.
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Fourth Quarter % Incr. / Twelve Months % Incr. /
-------------- -------------
(Dollars in Millions Except Per Share Data) 2012 2011 (Decr.) 2012 2011 (Decr.)
------------------------------------------ ---- ---- ------ ---- ---- ------
Earnings before provision for taxes on income - as reported $3,100 318 874.8% $13,775 12,361 11.4%
Net litigation loss (gain) 471 2,656 1,229 3,310
In-process research and development 55 14 1,163 14
Synthes integration/transaction costs and currency related 406 277 1,028 491
Intangible asset write-downs and other adjustments - - 909 -
DePuy ASR(TM) Hip program 83 412 110 521
Restructuring - (20) - 656
Earnings before provision for taxes on income - as adjusted $4,115 3,657 12.5% $18,214 17,353 5.0%
------ ----- ---- ------- ------ ---
Net Earnings attributable to Johnson & Johnson - as reported $2,567 218 1,077.5% $10,853 9,672 12.2%
Net litigation loss (gain) 371 2,239 1,052 2,745
In-process research and development 59 11 743 (1) 11
Synthes integration/transaction costs and currency related 306 338 899 477
Intangible asset write-downs and other adjustments - - 701 -
DePuy ASR(TM) Hip program 73 336 97 426
Restructuring - (13) - 536
Net Earnings attributable to Johnson & Johnson - as adjusted $3,376 3,129 7.9% $14,345 13,867 3.4%
------ ----- --- ------- ------ ---
Diluted Net Earnings per share attributable to Johnson & Johnson - as reported $0.91 0.08 1,037.5 $3.86
% 3.49 10.6%
Net litigation loss (gain) 0.13 0.81 0.37 0.99
In-process research and development 0.02 - 0.27 -
Synthes integration/transaction costs and currency related 0.11 0.12 0.32 0.17
Intangible asset write-downs and other adjustments - - 0.25 -
DePuy ASR(TM) Hip program 0.02 0.12 0.03 0.16
Restructuring - - - 0.19
Diluted Net Earnings per share attributable to Johnson & Johnson - as adjusted $1.19 1.13 5.3%
$5.10 5.00 2.0%
----- ---- ---
(1) Amount includes third quarter in-process research and development charge of $679M related to bapineuzumab IV offset by $339M reported as net loss attributable to noncontrolling interest
The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes
on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.
REPORTED SALES vs. PRIOR PERIOD ($MM)
------------------------------------
% Change % Change
-------- --------
2012 2011 Reported Operational (1) Currency 2012 2011 Reported Operational (1) Currency
---- ---- -------- -------------- -------- ---- ---- -------- -------------- --------
CONSUMER SEGMENT (2)
-------------------
BABY CARE
---------
US $103 103 0.0% 0.0% - $412 418 -1.4% -1.4% -
Intl 469 465 0.9% 3.5% -2.6% 1,842 1,922 -4.2% 1.1% -5.3%
--- --- ----- -----
WW 572 568 0.7% 2.8% -2.1% 2,254 2,340 -3.7% 0.6% -4.3%
ORAL CARE
---------
US 165 173 -4.6% -4.6% - 641 656 -2.3% -2.3% -
Intl 251 239 5.0% 6.6% -1.6% 983 968 1.5% 6.9% -5.4%
--- --- --- ---
WW 416 412 1.0% 2.0% -1.0% 1,624 1,624 0.0% 3.2% -3.2%
OTC/NUTRITIONALS
----------------
US 356 370 -3.8% -3.8% - 1,424 1,429 -0.3% -0.3% -
Intl 802 766 4.7% 5.7% -1.0% 2,930 2,973 -1.4% 3.4% -4.8%
--- --- ----- -----
WW 1,158 1,136 1.9% 2.6% -0.7% 4,354 4,402 -1.1% 2.1% -3.2%
SKIN CARE
---------
US 385 403 -4.5% -4.5% - 1,699 1,654 2.7% 2.7% -
Intl 509 541 -5.9% -3.4% -2.5% 1,919 2,061 -6.9% -2.0% -4.9%
--- --- ----- -----
WW 894 944 -5.3% -3.9% -1.4% 3,618 3,715 -2.6% 0.1% -2.7%
WOMEN'S HEALTH
--------------
US 82 89 -7.9% -7.9% - 336 439 -23.5% -23.5% -
Intl 325 309 5.2% 9.4% -4.2% 1,289 1,353 -4.7% 2.3% -7.0%
--- --- ----- -----
WW 407 398 2.3% 5.5% -3.2% 1,625 1,792 -9.3% -4.0% -5.3%
WOUND CARE/OTHER
----------------
US 112 110 1.8% 1.8% - 534 555 -3.8% -3.8% -
Intl 93 100 -7.0% -8.0% 1.0% 438 455 -3.7% 0.6% -4.3%
--- --- --- ---
WW 205 210 -2.4% -2.9% 0.5% 972 1,010 -3.8% -1.8% -2.0%
TOTAL CONSUMER
--------------
US 1,203 1,248 -3.6% -3.6% - 5,046 5,151 -2.0% -2.0% -
Intl 2,449 2,420 1.2% 3.2% -2.0% 9,401 9,732 -3.4% 1.9% -5.3%
----- ----- ----- -----
WW $3,652 3,668 -0.4% 0.9% -1.3% $14,447 14,883 -2.9% 0.5% -3.4%
====== ===== ======= ======
See footnotes at end of schedule
REPORTED SALES vs. PRIOR PERIOD ($MM)
------------------------------------
% Change % Change
-------- --------
2012 2011 Reported Operational (1) Currency 2012 2011 Reported Operational (1) Currency
---- ---- -------- -------------- -------- ---- ---- -------- -------------- --------
PHARMACEUTICAL SEGMENT (2) (4)
------------------------------
IMMUNOLOGY
----------
US $1,448 1,401 3.4% 3.4% - $5,972 5,751 3.8% 3.8% -
Intl 528 395 33.7% 35.7% -2.0% 1,902 1,047 81.7% 86.3% -4.6%
--- --- ----- -----
WW 1,976 1,796 10.0% 10.4% -0.4% 7,874 6,798 15.8% 16.9% -1.1%
REMICADE
--------
US 871 776 12.2% 12.2% - 3,583 3,276 9.4% 9.4% -
US Exports (3) 347 437 -20.6% -20.6% - 1,470 1,797 -18.2% -18.2% -
Intl 286 215 33.0% 34.4% -1.4% 1,086 419 * * -4.5%
--- --- ----- ---
WW 1,504 1,428 5.3% 5.5% -0.2% 6,139 5,492 11.8% 12.6% -0.8%
SIMPONI
-------
US 72 62 16.1% 16.1% - 292 235 24.3% 24.3% -
Intl 109 57 91.2% 96.8% -5.6% 315 175 80.0% 87.5% -7.5%
--- --- --- ---
WW 181 119 52.1% 54.8% -2.7% 607 410 48.0% 51.2% -3.2%
STELARA
-------
US 158 126 25.4% 25.4% - 627 443 41.5% 41.5% -
Intl 111 81 37.0% 40.1% -3.1% 398 295 34.9% 42.4% -7.5%
--- --- --- ---
WW 269 207 30.0% 31.2% -1.2% 1,025 738 38.9% 41.9% -3.0%
OTHER IMMUNOLOGY
----------------
US - - - - - - - - - -
Intl 22 42 -47.6% -49.4% 1.8% 103 158 -34.8% -33.0% -1.8%
--- --- --- ---
WW 22 42 -47.6% -49.4% 1.8% 103 158 -34.8% -33.0% -1.8%
INFECTIOUS DISEASES
-------------------
US 236 210 12.4% 12.4% - 974 1,401 -30.5% -30.5% -
Intl 620 506 22.5% 26.7% -4.2% 2,220 1,788 24.2% 32.1% -7.9%
--- --- ----- -----
WW 856 716 19.6% 22.6% -3.0% 3,194 3,189 0.2% 4.6% -4.4%
INTELENCE
---------
US 46 45 2.2% 2.2% - 176 163 8.0% 8.0% -
Intl 38 38 0.0% 1.7% -1.7% 173 151 14.6% 22.2% -7.6%
--- --- --- ---
WW 84 83 1.2% 2.0% -0.8% 349 314 11.1% 14.8% -3.7%
LEVAQUIN/FLOXIN
--------------------
US - (6) * * - 35 579 -94.0% -94.0% -
Intl 10 11 -9.1% -10.5% 1.4% 40 44 -9.1% -5.8% -3.3%
--- --- --- ---
WW 10 5 100.0% 97.2% 2.8% 75 623 -88.0% -87.8% -0.2%
PREZISTA
--------
US 165 143 15.4% 15.4% - 672 529 27.0% 27.0% -
Intl 188 173 8.7% 12.2% -3.5% 742 682 8.8% 16.3% -7.5%
--- --- --- ---
WW 353 316 11.7% 13.6% -1.9% 1,414 1,211 16.8% 21.0% -4.2%
OTHER INFECTIOUS DISEASES
-------------------------
US 25 28 -10.7% -10.7% - 91 130 -30.0% -30.0% -
Intl 384 284 35.2% 40.5% -5.3% 1,265 911 38.9% 47.3% -8.4%
--- --- ----- ---
WW 409 312 31.1% 35.9% -4.8% 1,356 1,041 30.3% 37.7% -7.4%
REPORTED SALES vs. PRIOR PERIOD ($MM)
------------------------------------
% Change % Change
-------- --------
2012 2011 Reported Operational (1) Currency 2012 2011 Reported Operational (1) Currency
---- ---- -------- -------------- -------- ---- ---- -------- -------------- --------
NEUROSCIENCE
------------
US 601 611 -1.6% -1.6% - 2,611 2,617 -0.2% -0.2% -
Intl 1,088 1,128 -3.5% -1.6% -1.9% 4,107 4,331 -5.2% -0.8% -4.4%
----- ----- ----- -----
WW 1,689 1,739 -2.9% -1.6% -1.3% 6,718 6,948 -3.3% -0.5% -2.8%
CONCERTA/METHYLPHENIDATE
-----------------------------
US 116 155 -25.2% -25.2% - 609 822 -25.9% -25.9% -
Intl 127 119 6.7% 8.1% -1.4% 464 446 4.0% 8.8% -4.8%
--- --- --- ---
WW 243 274 -11.3% -10.7% -0.6% 1,073 1,268 -15.4% -13.7% -1.7%
INVEGA
------
US 76 66 15.2% 15.2% - 299 285 4.9% 4.9% -
Intl 71 59 20.3% 23.0% -2.7% 251 214 17.3% 22.0% -4.7%
--- --- --- ---
WW 147 125 17.6% 18.9% -1.3% 550 499 10.2% 12.2% -2.0%
INVEGA SUSTENNA/ XEPLION
-----------------------------
US 132 99 33.3% 33.3% - 482 319 51.1% 51.1% -
Intl 96 36 * * -2.4% 314 59 * * -5.7%
--- --- --- ---
WW 228 135 68.9% 69.9% -1.0% 796 378 * * -2.2%
RISPERDAL CONSTA
----------------
US 103 108 -4.6% -4.6% - 439 443 -0.9% -0.9% -
Intl 255 277 -7.9% -5.8% -2.1% 986 1,140 -13.5% -8.6% -4.9%
--- --- --- -----
WW 358 385 -7.0% -5.5% -1.5% 1,425 1,583 -10.0% -6.4% -3.6%
OTHER NEUROSCIENCE
------------------
US 174 183 -4.9% -4.9% - 782 748 4.5% 4.5% -
Intl 539 637 -15.4% -13.7% -1.7% 2,092 2,472 -15.4% -11.9% -3.5%
--- --- ----- -----
WW 713 820 -13.0% -11.7% -1.3% 2,874 3,220 -10.7% -8.0% -2.7%
ONCOLOGY
--------
US 135 95 42.1% 42.1% - 506 331 52.9% 52.9% -
Intl 684 468 46.2% 49.7% -3.5% 2,123 1,717 23.6% 29.7% -6.1%
--- --- ----- -----
WW 819 563 45.5% 48.5% -3.0% 2,629 2,048 28.4% 33.3% -4.9%
DOXIL/CAELYX
-----------------
US 21 10 * * - 43 140 -69.3% -69.3% -
Intl 9 29 -69.0% -68.3% -0.7% 40 262 -84.7% -83.5% -1.2%
--- --- --- ---
WW 30 39 -23.1% -22.6% -0.5% 83 402 -79.4% -78.6% -0.8%
VELCADE
-------
US - - - - - - - - - -
Intl 502 352 42.6% 47.6% -5.0% 1,500 1,274 17.7% 24.5% -6.8%
--- --- ----- -----
WW 502 352 42.6% 47.6% -5.0% 1,500 1,274 17.7% 24.5% -6.8%
ZYTIGA
------
US 114 85 34.1% 34.1% - 463 191 * * -
Intl 150 67 * * -3.8% 498 110 * * -7.0%
--- --- --- ---
WW 264 152 73.7% 75.8% -2.1% 961 301 * * -3.7%
OTHER ONCOLOGY
--------------
US - - - - - - - - - -
Intl 23 20 15.0% 18.8% -3.8% 85 71 19.7% 25.5% -5.8%
--- --- --- ---
WW 23 20 15.0% 18.8% -3.8% 85 71 19.7% 25.5% -5.8%
REPORTED SALES vs. PRIOR PERIOD ($MM)
------------------------------------
% Change % Change
-------- --------
2012 2011 Reported Operational (1) Currency 2012 2011 Reported Operational (1) Currency
---- ---- -------- -------------- -------- ---- ---- -------- -------------- --------
TOTAL OTHER
-----------
US 593 570 4.0% 4.0% - 2,358 2,286 3.1% 3.1% -
Intl 592 710 -16.6% -15.5% -1.1% 2,578 3,099 -16.8% -12.4% -4.4%
--- --- ----- -----
WW 1,185 1,280 -7.4% -6.8% -0.6% 4,936 5,385 -8.3% -5.8% -2.5%
ACIPHEX/PARIET
-------------------
US 92 110 -16.4% -16.4% - 372 414 -10.1% -10.1% -
Intl 94 144 -34.7% -33.9% -0.8% 463 561 -17.5% -11.8% -5.7%
--- --- --- ---
WW 186 254 -26.8% -26.4% -0.4% 835 975 -14.4% -11.1% -3.3%
PROCRIT/EPREX
------------------
US 171 191 -10.5% -10.5% - 805 814 -1.1% -1.1% -
Intl 155 177 -12.4% -11.0% -1.4% 657 809 -18.8% -13.7% -5.1%
--- --- --- ---
WW 326 368 -11.4% -10.7% -0.7% 1,462 1,623 -9.9% -7.4% -2.5%
OTHER
-----
US 330 269 22.7% 22.7% - 1,181 1,058 11.6% 11.6% -
Intl 343 389 -11.8% -10.8% -1.0% 1,458 1,729 -15.7% -12.1% -3.6%
--- --- ----- -----
WW 673 658 2.3% 2.9% -0.6% 2,639 2,787 -5.3% -3.1% -2.2%
TOTAL PHARMACEUTICAL
--------------------
US 3,013 2,887 4.4% 4.4% - 12,421 12,386 0.3% 0.3% -
Intl 3,512 3,207 9.5% 12.1% -2.6% 12,930 11,982 7.9% 13.6% -5.7%
----- ----- ------ ------
WW $6,525 6,094 7.1% 8.5% -1.4% $25,351 24,368 4.0% 6.8% -2.8%
====== ===== ======= ======
See footnotes at end of schedule
REPORTED SALES vs. PRIOR PERIOD ($MM)
------------------------------------
% Change % Change
-------- --------
2012 2011 Reported Operational (1) Currency 2012 2011 Reported Operational (1) Currency
---- ---- -------- -------------- -------- ---- ---- -------- -------------- --------
MEDICAL DEVICES AND DIAGNOSTICS (2)(4)
---------------------------------------
CARDIOVASCULAR CARE
-------------------
US $186 191 -2.6% -2.6% - $752 841 -10.6% -10.6% -
Intl 320 349 -8.3% -6.6% -1.7% 1,233 1,447 -14.8% -11.5% -3.3%
--- --- ----- -----
WW 506 540 -6.3% -5.2% -1.1% 1,985 2,288 -13.2% -11.1% -2.1%
DIABETES CARE
-------------
US 295 330 -10.6% -10.6% - 1,312 1,312 0.0% 0.0% -
Intl 349 340 2.6% 5.2% -2.6% 1,304 1,340 -2.7% 2.8% -5.5%
--- --- ----- -----
WW 644 670 -3.9% -2.6% -1.3% 2,616 2,652 -1.4% 1.4% -2.8%
DIAGNOSTICS
-----------
US 258 280 -7.9% -7.9% - 1,025 1,091 -6.0% -6.0% -
Intl 272 274 -0.7% 1.3% -2.0% 1,044 1,073 -2.7% 1.0% -3.7%
--- --- ----- -----
WW 530 554 -4.3% -3.3% -1.0% 2,069 2,164 -4.4% -2.6% -1.8%
INFECTION PREVENTION/OTHER
--------------------------
US 86 94 -8.5% -8.5% - 399 377 5.8% 5.8% -
Intl 160 144 11.1% 13.6% -2.5% 553 529 4.5% 8.2% -3.7%
--- --- --- ---
WW 246 238 3.4% 4.9% -1.5% 952 906 5.1% 7.2% -2.1%
ORTHOPAEDICS
------------
US 1,246 775 60.8% 60.8% - 4,144 3,093 34.0% 34.0% -
Intl 1,142 678 68.4% 70.1% -1.7% 3,655 2,716 34.6% 38.7% -4.1%
----- --- ----- -----
WW 2,388 1,453 64.3% 65.1% -0.8% 7,799 5,809 34.3% 36.2% -1.9%
SPECIALTY SURGERY
-----------------
US 326 327 -0.3% -0.3% - 1,297 1,226 5.8% 5.8% -
Intl 329 307 7.2% 9.5% -2.3% 1,229 1,181 4.1% 8.9% -4.8%
--- --- ----- -----
WW 655 634 3.3% 4.4% -1.1% 2,526 2,407 4.9% 7.2% -2.3%
SURGICAL CARE
-------------
US 618 639 -3.3% -3.3% - 2,415 2,465 -2.0% -2.0% -
Intl 1,049 1,055 -0.6% 1.9% -2.5% 4,068 4,172 -2.5% 2.1% -4.6%
----- ----- ----- -----
WW 1,667 1,694 -1.6% 0.0% -1.6% 6,483 6,637 -2.3% 0.6% -2.9%
VISION CARE
-----------
US 229 214 7.0% 7.0% - 1,019 966 5.5% 5.5% -
Intl 516 496 4.0% 6.1% -2.1% 1,977 1,950 1.4% 3.7% -2.3%
--- --- ----- -----
WW 745 710 4.9% 6.4% -1.5% 2,996 2,916 2.7% 4.3% -1.6%
TOTAL MEDICAL DEVICES AND DIAGNOSTICS
-------------------------------------
US 3,244 2,850 13.8% 13.8% - 12,363 11,371 8.7% 8.7% -
Intl 4,137 3,643 13.6% 15.8% -2.2% 15,063 14,408 4.5% 8.6% -4.1%
----- ----- ------ ------
WW $7,381 6,493 13.7% 14.9% -1.2% $27,426 25,779 6.4% 8.7% -2.3%
====== ===== ======= ======
* Percentage greater than 100%
(1) Operational growth excludes the effect of currency
(2) Select areas (unaudited)
(3) Reported as U.S. sales
(4) Prior year amounts have been reclassified to conform to current year product disclosure
SOURCE Johnson & Johnson
